Anesthesia and analgesia
-
Anesthesia and analgesia · Jul 2010
Blockade of the sinuvertebral nerve for the diagnosis of lumbar diskogenic pain: an exploratory study.
In this exploratory study we evaluated sensitivity and target specificity of sinuvertebral nerve block (SVNB) for the diagnosis of lumbar diskogenic pain. Diskography has been the diagnostic gold standard. Fifteen patients with positive diskography underwent SVNB via interlaminar approach to the posterior aspect of the disk. ⋯ The sensitivity was 73.3% (95% CI: 50.9%-95.7%). The target specificity was 40% (15.2%-64.8%). The results indicate that SVNB cannot yet replace diskography but encourage future studies to improve its target specificity.
-
Anesthesia and analgesia · Jul 2010
Activation of central opioid receptors induces cardioprotection against ischemia-reperfusion injury.
Small doses of intrathecal morphine provide cardioprotection similar to that conferred by IV morphine and ischemic preconditioning (IPC). We investigated the relative role of central versus peripheral opioid receptors in intrathecal morphine preconditioning (ITMPC). ⋯ Intrathecally administered morphine can produce cardioprotective effects via the activation of central opioid receptors, without the apparent involvement of peripheral opioid receptors.
-
Anesthesia and analgesia · Jul 2010
Editorial CommentManaging neuromuscular block: where are the guidelines?
-
Anesthesia and analgesia · Jul 2010
Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.
Cannabinoid receptor 2 (CB2) agonists have recently gained attention as potential therapeutic targets in the management of neuropathic pain. In this study, we characterized the pharmacological profile of the novel compound N'-[(3Z)-1-(1-hexyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene]benzohydrazide (MDA19), a CB2 agonist. ⋯ We found that MDA19 exhibited a distinctive in vitro functional profile at rat CB2 receptors and behaved as a CB1/CB2 agonist in vivo, characteristics of a protean agonist. MDA19 has potential for alleviating neuropathic pain without producing adverse effects in the central nervous system.